While treatment with eFT508 suppresses PD-L1 expression in cell lines derived from a Myc-driven hepatocellular carcinoma transgenic mouse model (29), we found that neither CGP57380 nor eFT508 affected PD-L1 expression levels in mouse pancreatic and thyroid cancer cells (Figure 5, A and B). The gene discussed is MYC; the disease is thyroid cancer.